Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intratumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
- Genome Med., Published: 06 January 2022, 14, Article number: 1 | https://doi.org/10.1186/s13073-021-00995-8